

11th April, 2017

✓ The Dy. General Manager (Listing Dept.)
 BSE Limited,
 Corporate Relationship Dept.,
 1st Floor, New Trading Ring,
 P. J. Towers, Dalal Street, Fort,
 Mumbai - 400 001
 (BSE Scrip Code: 500420)

~~The Manager – Listing Dept.,
 National Stock Exchange of India Ltd.,
 Exchange Plaza, 5th Floor,
 Plot No. C/1, G. Block,
 Bandra - Kurla Complex, Bandra (E),
 Mumbai – 400 051
 (NSE Scrip Code: TORNTPHARM)~~

Dear Sir,

Sub: Submission of Quarterly statement of Investor Complaints under Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with the requirement under Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the statement of Investor Complaints/Grievances, for the quarter ended 31st March, 2017.

No. of Investor Complaints pending at the beginning of the quarter	No. of Investor Complaints received during the quarter	No. of Investor Complaints disposed of during the quarter	No. of Investor Complaints remaining unresolved at the end of the quarter*
0	2	1	1

* The complaint was satisfactorily resolved on 01-Apr-17.

The statement will be placed before the Board at their ensuing Board Meeting.

This is for your information and records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED


 MAHESH AGRAWAL
 VP (LEGAL) & COMPANY SECRETARY